Update to Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) – Approved

Yahoo! Finance (2019). Stock price graph for Agios Pharmaceuticals 5/3/2018 to 5/3/2019. Retrieved from https://finance.yahoo.com/quote/AGIO?p-AGIO

Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO®

TIBSOVO® received approval to become the first and only therapy approved for newly diagnosed AML patients with an IDH1 mutation who are ineligible for Intensive Chemotherapy. ¹ With this most recent press release the approval, the stock has increased over 5%. This news may be the catalyst to support Agios in reversing their downtrend. I will be keeping a close eye on this ticker in hopes of confirming a reversal. Continue to follow my blog for a technical analysis of AGIO .

For the original post, please click the following link:
https://pillpicks.home.blog/2019/04/27/agios-pharmaceuticals-inc-nasdaq-agio/

REFERENCES

  1. Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy.; (2019). Available at
    https://agiospharmaceuticalsinc.gcs-web.com/node/12416

One thought on “Update to Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) – Approved

  1. Pingback: Weekly Watchlist Tickers – Pill Picks

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s